225 related articles for article (PubMed ID: 21568903)
1. Targeting PDK1 in cancer.
Raimondi C; Falasca M
Curr Med Chem; 2011; 18(18):2763-9. PubMed ID: 21568903
[TBL] [Abstract][Full Text] [Related]
2. 3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.
Fyffe C; Falasca M
Cancer Manag Res; 2013; 5():271-80. PubMed ID: 24039447
[TBL] [Abstract][Full Text] [Related]
3. Modulation of PI3K/PTEN Pathway Does Not Affect Catalytic Activity of PDK1 in Jurkat Cells.
Yang KJ; Piao L; Shin S; Shin SY; Li Y; Lee H; Tran Q; Park J; Hong S; Brazil DP; Hemmings BA; Kim SH; Park J
Anticancer Res; 2017 Oct; 37(10):5415-5423. PubMed ID: 28982851
[TBL] [Abstract][Full Text] [Related]
4. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
Gagliardi PA; di Blasio L; Orso F; Seano G; Sessa R; Taverna D; Bussolino F; Primo L
Neoplasia; 2012 Aug; 14(8):719-31. PubMed ID: 22952425
[TBL] [Abstract][Full Text] [Related]
5. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Maurer M; Su T; Saal LH; Koujak S; Hopkins BD; Barkley CR; Wu J; Nandula S; Dutta B; Xie Y; Chin YR; Kim DI; Ferris JS; Gruvberger-Saal SK; Laakso M; Wang X; Memeo L; Rojtman A; Matos T; Yu JS; Cordon-Cardo C; Isola J; Terry MB; Toker A; Mills GB; Zhao JJ; Murty VV; Hibshoosh H; Parsons R
Cancer Res; 2009 Aug; 69(15):6299-306. PubMed ID: 19602588
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibitors of PDK1.
Peifer C; Alessi DR
ChemMedChem; 2008 Dec; 3(12):1810-38. PubMed ID: 18972468
[TBL] [Abstract][Full Text] [Related]
7. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
[TBL] [Abstract][Full Text] [Related]
8. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells.
Liu Y; Wang J; Wu M; Wan W; Sun R; Yang D; Sun X; Ma D; Ying G; Zhang N
Mol Cancer Res; 2009 Jun; 7(6):944-54. PubMed ID: 19531564
[TBL] [Abstract][Full Text] [Related]
10. Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.
Baxi SM; Tan W; Murphy ST; Smeal T; Yin MJ
PLoS One; 2012; 7(10):e48402. PubMed ID: 23119004
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways.
Bayascas JR
Cell Cycle; 2008 Oct; 7(19):2978-82. PubMed ID: 18802401
[TBL] [Abstract][Full Text] [Related]
12. Functional counterparts of mammalian protein kinases PDK1 and SGK in budding yeast.
Casamayor A; Torrance PD; Kobayashi T; Thorner J; Alessi DR
Curr Biol; 1999 Feb; 9(4):186-97. PubMed ID: 10074427
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes.
Finlay DK; Sinclair LV; Feijoo C; Waugh CM; Hagenbeek TJ; Spits H; Cantrell DA
J Exp Med; 2009 Oct; 206(11):2441-54. PubMed ID: 19808258
[TBL] [Abstract][Full Text] [Related]
14. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.
Medina JR
J Med Chem; 2013 Apr; 56(7):2726-37. PubMed ID: 23448267
[TBL] [Abstract][Full Text] [Related]
15. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
16. Notch-induced T cell development requires phosphoinositide-dependent kinase 1.
Kelly AP; Finlay DK; Hinton HJ; Clarke RG; Fiorini E; Radtke F; Cantrell DA
EMBO J; 2007 Jul; 26(14):3441-50. PubMed ID: 17599070
[TBL] [Abstract][Full Text] [Related]
17. Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination.
Di Blasio L; Gagliardi PA; Puliafito A; Primo L
Cancers (Basel); 2017 Mar; 9(3):. PubMed ID: 28287465
[TBL] [Abstract][Full Text] [Related]
18. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase.
Alessi DR; Deak M; Casamayor A; Caudwell FB; Morrice N; Norman DG; Gaffney P; Reese CB; MacDougall CN; Harbison D; Ashworth A; Bownes M
Curr Biol; 1997 Oct; 7(10):776-89. PubMed ID: 9368760
[TBL] [Abstract][Full Text] [Related]
19. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
20. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
